natgillin/translations-raw huggingface dataset:
C Bivirkningen stammer fra overvågningsdata for saxagliptin eller dapagliflozin efter markedsføringen.
C Adverse reaction originates from saxagliptin or dapagliflozin post-marketing surveillance data.
c Common Terminology Criteria for Adverse Events (CTCAE) version 3.0; grad 1 = let, grad 2 = moderat, grad 3 = svær, grad 4 = livstruende
c Common Terminology Criteria for Adverse Events (CTCAE) version 3.0; grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening
c Estimatet af hazards ratio er baseret på en Cox-model justeret for stratifikationsfaktorer: ISS-score og antal tidligere linjer. d Logrank-test justeret for stratifikationsfaktorer: ISS-score og antal tidligere linjer. e Median varighed af opfølgning er 11,8 måneder
c Hazards ratio estimate is based on a Cox model adjusted for stratification factors: ISS staging and number of prior lines. d Log rank test adjusted for stratification factors: ISS staging and number of prior lines. e Median duration of follow up is 11.8 months
C Forskel er Eylea-gruppen minus aktiv kontrolgruppe (laser)
C Difference is Eylea group minus active control (laser) group
c Lopinavir/RTV med tenofovir/emtricitabin (fast dosis på 300 mg/200 mg tabletter en gang dagligt).
c Lopinavir/RTV with tenofovir/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
c Nominel p-værdi baseret på den stratificerede log-rank-test justeret for stratifikationsfaktorer: β2 ­mikroglobulin, albumin og region d. p-værdi for responsrate (CR+PR) fra Cochran-Mantel-Haenszel chi-kvadrattest justeret for stratifikationsfaktorer e Responspopulation omfatter patienter, som havde målbar sygdom ved baseline f CR = komplet respons; PR = partielt respons.
c Nominal p-value based on the stratified log-rank test adjusted for stratification factors: β2­microglobulin, albumin, and region d p-value for Response Rate (CR+PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors e Response population includes patients who had measurable disease at baseline f CR=Complete Response; PR=Partial Response.
c Nominel p-værdi baseret på den stratificerede log-rank-test justeret for stratifikationsfaktorer:  2-mikroglobulin, albumin og region d p-værdi for responsrate (CR+PR) fra Cochran-Mantel-Haenszel chi-square-test justeret for stratifikationsfaktorer e Responspopulation omfatter patienter, som havde målbar sygdom ved baseline f CR = fuldstændigt respons; PR = partielt respons.
c Nominal p-value based on the stratified log-rank test adjusted for stratification factors: β2-microglobulin, albumin, and region d p-value for Response Rate (CR+PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors e Response population includes patients who had measurable disease at baseline f CR=Complete Response; PR=Partial Response.
c Nominel p-værdi baseret på den stratificerede log-rank-test justeret for stratifikationsfaktorer: 2-mikroglobulin, albumin og region d p-værdi for responsrate (CR+PR) fra Cochran-Mantel-Haenszel chi-square-test justeret for stratifikationsfaktorer e Responspopulation omfatter patienter, som havde målbar sygdom ved baseline f CR = fuldstændigt respons; PR = partielt respons.
c Nominal p-value based on the stratified log-rank test adjusted for stratification factors: 2-microglobulin, albumin, and region d p-value for Response Rate (CR+PR) from the Cochran Mantel-Haenszel chi-square test adjusted for the stratification factors e Response population includes patients who had measurable disease at baseline f CR=Complete Response; PR=Partial Response.
c Odds-ratio, stigning i sandsynligheden for at opnå MCID sammenlignet med placebo.
Odds ratio, increase in the likelihood of achieving the MCID compared to placebo.
c Omfatter patienter, der kunne evalueres for respons
c Includes patients who were evaluable for response
c p = 0,002 d PedsQL: PedsQL Total Scale Score er et generelt mål for helbredsrelateret livskvalitet, som er udviklet til brug hos børn og unge.
c p = 0.002 d PedsQL: The PedsQL Total Scale Score is a general health-related quality of life measure developed for use in children and adolescent populations.
c Patienter med minimum et delvist respons på Humira 40 mg ugentlig efter 12 ugers behandling. d Patienter, som opfylder protokol-specifikke kriterier for tab af respons eller ingen forbedring, var forpligtet til at udgå af studierne og blev optalt som non-respondere.
a Patients with at least a partial response to Humira 40 mg weekly after 12 weeks of treatment. b Patients meeting protocol-specified criteria for loss of response or no improvement were required to discontinue from the studies and were counted as nonresponders.
c Studie 1-data var samlet fra CFQ-R for voksne/unge og CFQ-R for børn fra 12 til 13 år.
Study 1 data were pooled from CFQ-R for adults/adolescents and CFQ-R for children 12 to 13 years of age; Study 2 data were obtained from CFQ-R for children 6 to 11 years of age.
C&M Veterinary Distributors Limited IE-Limerick
Esperantolaan 4 B-3001 Leuven
C) for at mindske risikoen for infektion.
C), to reduce the risk of infection.
C) Forskellen er værdien af Eylea-gruppen minus værdien af ranibizumab-gruppen.
C) The difference is the value of the Eylea group minus the value of the ranibizumab group.
C) LS-gennemsnit: Gennemsnit afledt fra ANCOVA-modellen ved mindste kvadraters metode
C) LS mean: Least square means derived from ANCOVA model
C) LS-middelforskel og 95 % CI baseret på en ANCOVA-model med behandlingsgruppe, BCVA-kategori ved baseline (> 20/200 og ≤ 20/200) og region (Nordamerika vs.
C) LS mean difference and 95% CI based on an ANCOVA model with treatment group, baseline BCVA category (> 20/200 and ≤ 20/200) and region (North America vs.
C-peptid negativ type 1-diabetes mellitus..
Diabetes mellitus type 1, C-peptide negative.
C-reaktivt protein (CRP), neutrofilocytter og symptomer på infektion, når en patient skal evalueres for en potentiel infektion.
C-reactive protein (CRP), neutrophils and signs and symptoms of infection should be considered when evaluating a patient for a potential infection.
C-reaktivt protein, mg/l
C-reactive protein, mg/l
C-WORTHY
C-EDGE TE
C. albicans) og fungicid aktivitet over for alle undersøgte Aspergillus arter.
C. albicans) and fungicidal activity against all Aspergillus species tested.
C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi og arter af Fusarium, Rhizomucor, Mucor og Rhizopus.
C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus.
C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, og arter af Fusarium, Rhizomucor, Mucor og Rhizopus.
C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus.
C. Sæt altid penhætten tilbage på pennen og opbevar så pennen til næste injektion.
Always put the pen cap back on the pen, then store the pen until your next injection.
C. tropicalis, C. glabrata og C. krusei, der alle typisk har mindste hæmmende koncentrations(MIC)- værdier på mindre end 1 mg/l for voriconazol.
C. tropicalis, C. glabrata and C. krusei, all of which usually exhibit minimal inhibitory concentration (MICs) of less than 1 mg/L for voriconazole.
c.1001 G>A
c.983 G>C
c.1012 G>A
c.1001 G>A
c.1016 T>A
c.1012 G>A
c.1024 C
c.1024 C>T
c.1028 C>T
c.1016 T>A
c.1033 T>C
c.1028 C>T
c.1046 G>C
c.1033 T>C
c.1048 C
c.1048 G>C
c.1054 C
c.1054 G>C
c.1055 C>T
c.1046 G>C
c.1061 T>A
c.1055 C>T
c.1065 C
c.1065 C>A
c.1066 C>G
c.1061 T>A
c.1066 C>T
c.1066 C>G
c.1067G>A
c.1066 C>T
c.1067G>C
c.1067G>A
c.1069 C
c.1069 C>T
c.1073 A>C
c.1067G>C
c.1073 A>G
c.1073 A>C
c.1074 G>T
c.1073 A>G
c.1076 T>C
c.1074 G>T
c.1078 G>A
c.1076 T>C
c.1078 G>T
c.1078 G>A
c.1079 G>A
c.1078 G>T
c.1082 G>A
c.1079 G>A
c.1082 G>C
c.1082 G>A
c.1084 C>A
c.1082 G>C
c.1085 C>T
c.1084 C>A
c.1087 C>T
c.1085 C>T
c.1088 C
c.1088 G>C
c.1088 G>A
c.1087 C>T
c.1102 G>A
c.1088 G>A
c.1115 C
c.1115 T>C
c.1130 C
c.1130 C>A
c.1146 C
c.1146 C>G
c.1153 A>G
c.G1117A
c.1157 C
c.1157 A>C
c.1165 C
c.1165 C>G
c.1166 C
c.1166 C>T
c.118 C>G
c.92 C>T
c.118 C>T
c.118 C>G
c.1196 G>A eller 1197 G>A
c.1196 G>A or1197 G>A
c.1228 C
c.1228 A>C
c.1229 C
c.1229 C>A
c.1241 C
c.1241 T>C
c.1243 C
c.1243 C>T
c.1246 C
c.1246 C>T
c.1247_1248CT
c.1247_1248CT>AA
c.1247A C
c.1247A>C
c.140 G>A eller 141 G>A
c.140 G>A or 141 G>A
c.194 G>C (formodet splejsningssted)
c.194 G>C (putative splicing site )
c.194 G>T (formodet splejsningssted)
c.194 G>T (putative splicing site )
c.218 C>A
c.215 T>G
c.227 T>G
c.218 C>A
c.279 C>G
c.278 A>T
c.280T>G
c.279 C>G
c.281 G>A
c.281 G>C
c.281 G>C
c.280T>G
c.284 G>A
c.281 G>A
c.284 G>C
c.284 G>T
c.284 G>T
c.284 G>A
c.295 C>T
c.284 G>C
c.299 G>A
c.295 C>T
c.299 G>C
c.299 G>A
c.305 C>G
c.299 G>C
c.307 G>C
c.305 C>G
c.307 G>T
c.307 G>C
c.317 T>G
c.307 G>T
c.319 C>T
c.317 T>G
c.320 A>T
c.319 C>T
c.334 C>A
c.334 C>T
c.334 C>T
c.320 A>T
c.338 T>C
c.334 C>A
c.350 T>G
c.338 T>C
c.355 C>T
c.350 T>G
c.359 T>C
c.[358 C>T; 359 T>C]
c.361 G>C
c.359 T>C
c.379 A>T
c.374 A>C
c.386 T>C
c.379 A>T
c.389 A>G
c.386 T>C
c.392 T>C
c.389 A>G
c.394 G>A
c.392 T>C
c.395 G>A
c.394 G>A
c.400 T>G
c.400 T>C
c.401 A>C
c.400 T>G
c.402 T>G
c.401 A>C
c.406 C
c.402 T>G
c.406 G>T
c.406 G>C
c.412 G>A
c.406 G>T
c.413 G>A
c.412 G>A
c.416 A>C
c.413 G>A
c.422 C>A
c.416 A>C
c.422 C>T
c.422 C>A
c.424 T>C
c.422 C>T
c.425 G>A
c.424 T>C
c.426 C>A
c.425 G>A
c.426 C>G
c.426 C>A
c.427 G>C
c.426 C>G
c.439 G>A
c.427 G>C
c.440 G>A
c.439 G>A
c.443 G>A
c.440 G>A
c.444 T>G
c.443 G>A
c.453 C>G
c.444 T>G
c.456 C>A
c.453 C>G
c.463 G>C
c.456 C>A
c.467 C>A
c.463 G>C
c.469 C>T
c.467 C>A
c.484 T>C
c.469 C>T
c.485 G>A
c.484 T>C
c.485 G>T
c.485 G>A
c.486 G>C
c.485 G>T
c.488 G>T
c.486 G>C
c.491 T>G
c.488 G>T
c.493 G>T
c.491 T>G
c.494 A>T
c.493 G>T
c.500 T>A
c.494 A>T
c.500 T>C
c.500 T>A
c.503 A>G
c.500 T>C
c.508 G>A
c.504 A>C
c.508 G>C
c.508 G>A
c.509 A>G
c.508 G>C
c.509 A>T
c.509 A>G
c.511 G>C
c.509 A>T
c.511 G>T
c.511 G>C
c.512 G>A
c.511 G>T
c.547 G>A (formodet splejsningssted)
c.547 G>A (putative splicing site )
c.581 C>T
Nucleotide change
c.584 G>T
c.G584T
c.611 G>A eller 612G>A
c.611 G>A or 612G>A
c.702 T>G
c.700 G>T
c.704 C>A
c.702 T>G
c.734 G>A eller 735G>A
c.734 G>A or 735G>A
c.801 G>A (formodet splejsningssted)
c.801 G>A (putative splicing site )
c.860 G>A eller 861G>A
c.860 G>A or 861G>A
c.886 A>G
c.884 T>G
c.886 A>T
c.886 A>G
c.887 T>C
c.886 A>T
c.888 G>A
c.887 T>C
c.893 A>G
c.888 G>A
c.897 C>G
c.893 A>G
c.898 C>T
c.897 C>G
c.899 T>C
c.898 C>T
c.901 C>G
c.899 T>C
c.902 G>A
c.902 G>C
c.902 G>C
c.901 C>G
c.902 G>T
c.902 G>A
c.908 T>A
c.902 G>T
c.911 G>A
c.908 T>A
c.911 G>C
c.911 G>A
c.924 A>T
c.G919A
c.925 G>C
c.924 A>T
c.928 C>T
c.925 G>C
c.931 C
c.928 C>T
c.935 A>G
c.931 C>G
c.936 G>T
c.935 A>G
c.937 G>T
c.936 G>T
c.938 A>G
c.937 G>T
c.946 G>A
c.938 A>G
c.947 T>G
c.946 G>A
c.950 T>C
c.947 T>G
c.955 A>T
c.950 T>C
c.956 T>C
c.955 A>T
c.959 A>T
c.956 T>C
c.962 A>G
c.959 A>T
c.962 A>T
c.962 A>G
c.963 G>C
c.962 A>T
c.964 G>C
c.963 G>C
c.966 C>A
c.964 G>C
c.973 G>A
c.966 C>A
c.973 G>C
c.973 G>A
c.979 C>G
c.973 G>C
c.983 G>C
c.979 C>G
c.997 C
c.997 C>T
c.[358 C>T; 359 T>C]
c.358 C>G
c.A1073C
c.G1067C
c.A1073G
c.A1073C
c.A1153G
G373S
c.A320T
c.C319T
c.A379T
c.A374C
c.A389G
c.T386C
c.A401C
c.T400G
c.A416C
c.G413A
c.A494T
c.G493T
c.A509G
c.G508C
c.A509T
c.A509G
c.A886G
c.T884G
c.A886T
c.A886G
c.A893G
c.G888A
c.A924T
A307T
c.A935G
c.C931G
c.A938G
c.G937T
c.A955T
c.T950C
c.A959T
c.T956C
c.A962G
c.A959T
c.A962T
c.A962G
c.C1028T
c.T1016A
c.C1055T
c.G1046C
c.C1066G
c.T1061A
c.C1066T
c.C1066G
c.C1084A
c.G1082C
c.C1085T
c.C1084A
c.C1087T
c.C1085T
c.C118G
c.C92T
c.C218A
c.T215G
c.C279G
c.A278T
c.C295T
c.G284C
c.C305G
c.G299C
c.C319T
c.T317G
c.C334A
c.C334T
c.C334T
c.A320T
c.C355T
c.T350G
c.C358T/T359C
c.C358G
c.C422A
c.A416C
c.C422T
c.C422A
c.C426A
c.G425A
c.C426G
c.C426A
c.C453G
c.T444G
c.C456A
c.C453G
c.C467A
c.G463C
c.C469T
c.C467A
c.C897G
c.A893G
c.C898T
c.C897G
c.C901G
c.T899C
c.C928T
c.G925C
c.C931G
c.C928T
c.C966A
c.G964C
c.C979G
c.G973C
c.G1001A
c.G983C
c.G1012A
c.G1001A
c.G1046C
c.T1033C
c.G1067A
c.C1066T
c.G1067C
c.G1067A
c.G1074T
c.A1073G
c.G1078A
c.T1076C
c.G1078T
c.G1078A
c.G1079A
c.G1078T
c.G1082A
c.G1079A
c.G1082C
c.G1082A
c.G1088A
c.C1087T
c.G1196A eller G1197A
c.G1196A or G1197A
c.G194C (formodet splejsningssted)
c.G194C (putative splicing site )
c.G194T (formodet splejsningssted)
c.G194T (putative splicing site )
c.G281A
c.G281C
c.G281C
c.T280G
c.G284A
c.G281A
c.G284C
c.G284T
c.G284T
c.G284A
c.G299A
c.C295T
c.G299C
c.G299A
c.G307C
c.C305G
c.G307T
c.G307C
c.G394A
c.T392C
c.G406C
c.T402G
c.G406T
c.G406C
c.G412A
c.G406T
c.G413A
c.G412A
c.G425A
c.T424C
c.G427C
c.C426G
c.G439A
c.G427C
c.G43A
A15T
c.G440A
c.G439A
c.G443A
c.G440A
c.G463C
c.C456A
c.G485A
c.T484C
c.G485T
c.G485A
c.G486C
c.G485T
c.G488T
c.G486C
c.G493T
c.T491G
c.G508A
c.A504C
c.G508C
c.G508A
c.G511C
c.A509T
c.G511T
c.G511C
c.G547A (formodet splejsningssted)
c.G547A (putative splicing site )
c.G584T
G195V
c.G734A eller G735A
c.G734A or G735A
c.G860A eller G861A
c.G860A or G861A
c.G888A
c.T887C
c.G902A
c.G902C
c.G902C
c.C901G
c.G902T
c.G902A
c.G911A
c.T908A
c.G911C
c.G911A
c.G925C
c.A924T
c.G936T
c.A935G
c.G937T
c.G936T
c.G946A
c.A938G
c.G963C
c.A962T
c.G964C
c.G963C
c.G973A
c.C966A
c.G973C
c.G973A
c.G983C
c.C979G
C.J. Hambros Plass 2C N-0164 Oslo
C.J. Hambros Plass 2C 0164 Oslo
C.Sæt altid penhætten tilbage på pennen og opbevar så pennen til næste injektion.
Always put the pen cap back on the pen, then store the pen until your next injection.
C.Sæt altid penhætten tilbage på pennen og opbevar så pennen til næste injektion.
Put the pen cap back on, then store the pen until your next injection.
c.T1016A
c.G1012A
c.T1033C
c.C1028T
c.T1061A
c.C1055T
c.T1076C
c.G1074T
c.T280G
c.C279G
c.T317G
c.G307T
c.T338C
c.C334A
c.T350G
c.T338C
c.T359C
c.C358T/T359C
c.T386C
c.A379T
c.T392C
c.A389G
c.T400G
c.T400C
c.T402G
c.A401C
c.T424C
c.C422T
c.T444G
c.G443A
c.T484C
c.C469T
c.T491G
c.G488T
c.T500A
c.A494T
c.T500C
c.T500A
c.T604C A644G
c.T604C/A644G
c.T702G
c.G700T
c.T887C
c.A886T
c.T899C
c.C898T
c.T908A
c.G902T
c.T947G
c.G946A
c.T950C
c.T947G
c.T956C
c.A955T
C/ Del Sol, 5, Polígono Industrial Norte, Tres Cantos, 28760, Madrid
C/ Del Sol, 5, Poligono Industrial Norte, Tres Cantos, 28760, Madrid
C/ Mocholi 2, Polígono Industrial Mocholi, Noain, 31110 Navarra,
C/ Mocholi 2, Poligono Industrial Mocholi, Noain, 31110 Navarra
C/ Veguillas - 2 Nave 16, Ajalvir 28864 (Madrid) Spanien
C/ Veguillas – 2 Nave 16, Ajalvir 28864 (Madrid) Spain
C/Zeppelin,
C/ Zeppelin,
C04-001 C04-002
29 (29.9)
C08-002A/B
C08-002A/B N=17
C08-003A/B
C08-003A/B N=20
C1 er den vigtigste hæmmer af kontaktaktivering og regulerer kontaktsystemet og den intrinsiske koagulationsvej ved at binde og inaktivere kallikrein og faktor XIIa.
C1 is the most important inhibitor of contact activation and regulates the contact system and the intrinsic coagulation pathway by binding to and inactivating kallikrein and factor XIIa.
C1-esterasehæmmerproteinet er nødvendigt for at kontrollere "kontakt- og komplementsystemerne", som er samlinger af proteiner i blodet, der bekæmper infektioner og forårsager betændelse.
The C1 esterase inhibitor protein is required to control the ‘complement’ and ‘contact’ systems, collections of proteins in the blood that fight against infection and cause inflammation.
C1-hæmmer er et naturligt forekommende protein, som normalt er til stede i blodet.
C1 inhibitor is a naturally occurring protein that is normally present in the blood.
C1-hæmmeren er et enkeltkædet glykoprotein, som findes i plasma, der i den modne form består af 478 aminosyrer med en tilsyneladende molekylvægt på 105 kD.
C1 inhibitor is a single chain glycoprotein found in plasma which, in its mature state, consists of 478 amino acids with an apparent molecular weight of 105 kD.
C1-hæmmeren hæmmer komplementsystemet ved at binde C1r og C1s, to af de aktive enzymunderenheder af den første komponent af komplementsystemet (C1) i den klassiske aktiveringsvej, samt til mannose-bindende lectin-associerede serinproteaser i lectin-aktiveringsvejen.
C1 inhibitor inhibits the complement system by binding C1r and C1s, two of the active enzyme subunits of the first component of the complement system (C1) in the classical pathway, as well as to mannose-binding lectin-associated serine proteases in the lectin pathway.
C1-hæmmeren tilhører den overordnede familie af serin-proteasehæmmer-proteiner, eller serpiner.
C1 inhibitor is a member of the serine protease inhibitor, or serpin, superfamily of proteins.
C1-hæmmerproteinet er nødvendigt for at kontrollere "kontakt- og komplementsystemerne", der er samlinger af proteiner i blodet, som bekæmper infektioner og forårsager betændelse.
The C1 inhibitor protein is required to control the ‘complement’ and ‘contact’ systems, collections of proteins in the blood that fight against infection and cause inflammation.
C12:  21%
Maraviroc:
C12:  21%
Saquinavir/ritonavir/Efavirenz
C12t (nM)
C12hr (nM)
C12t: ↑ 3%
C12h: ↑ 3
C12t: ↓ 13%
C12h: ↓ 13
C12t: ↓ 21%
C12h: ↓ 21
C142R
T141I
C142W
C142X
C142X
C142Y
C142Y
C142R
C208 - C216 (QUEST-1 og
C208 - C216 (QUEST-1 and QUEST-2;
C24 0,69 (0,54; 0,88)
C24 0.69 (0.54, 0.88)
C24 0,77 (0,61; 0,99)
C24 0.77 (0.61, 0.99)
C24 0,80 (0,55; 1,16)
C24 0.80 (0.55, 1.16)
C24 0,80 (0,70; 0,91)
C24 0.80 (0.70, 0.91)
C24 0,84 (0,71; 0,99)
C24 0.84 (0.71, 0.99)
C24 0,87 (0,70; 1,09)
C24 0.87 (0.70, 1.09)
C24 0,92 (0,18; 1,05)
C24 1.24 (1.10, 1.39)
C24 0,92 (0,83; 1,02)
C24 0.92 (0.83, 1.02)
C24 0,98 (0,88; 1,09)
C24 0.98 (0.88, 1.09)
C24 1,03 (0,92; 1,17)
C24 1.03 (0.92, 1.17)
C24 1,04 (0,97; 1,12)
C24 1.04 (0.97, 1.12)
C24 1,05 (0,97; 1,14)
C24 1.05 (0.97, 1.14)
C24 1,10 (0,96; 1,26)
C24 1.10 (0.96, 1.26)
C24 1,15 (1,02; 1,29)
C24 1.23 (1.13, 2.34)
C24 1,19 (1,13; 1,25)
C24 1.15 (1.02, 1.29)
C24 1,20 (0,98; 1,47)
C24 1.20 (0.98, 1.47)
C24 1,22 (0,99; 1,51)
C24 1.22 (0.99, 1.51)
C24 1,22 (1,02; 1,45)
C24 1.22 (1.02, 1.45)
C24 1,23 (1,13; 2,34)
C12 0.94 (0.85, 1.05)
C24 1,24 (1,10; 1,39)
Atazanavir/ritonavir
C24 1,29 (1,18; 1,41)
C24 1.23 (1.09, 1.40)
C24 6,45 (5,51; 7,54)
C24 11.64 (7.96, 17.02)
C2402-studiet var et randomiseret fase III-multicenterstudie med parallelle grupper og tre behandlingsarme med dobbeltblindet pasireotid 40 mg og 60 mg til intramuskulær anvendelse versus open label octreotid 30 mg til intramuskulær anvendelse eller lanreotid 120 mg som dyb subkutan injektion hos patienter med utilstrækkeligt kontrolleret akromegali.
Study C2402 was a phase III, multicentre, randomised, parallel-group, three-arm study of double-blind pasireotide intramuscular use 40 mg and 60 mg versus open-label octreotide intramuscular use 30 mg or lanreotide deep subcutaneous injection 120 mg in patients with inadequately controlled acromegaly.
C94G
D93E
C94S
C94G
C94Y
C94S
c: 3 morgen, 3 aften d: 3 morgen, 4 aften
c: 3 morning, 3 evening d: 3 morning, 4 evening
C: Blanding af det anviste antal breve REYATAZ oralt pulver med føde som f.eks. æblemos eller yoghurt i en lille beholder:
C: To mix the recommended number of REYATAZ oral powder sachets with food such as applesauce or yogurt in a small container:
c: forsøgspersoner < 75 kg fik 100 µg/uge peginterferon alfa-2b og forsøgspersoner ≥ 75 kg fik 150 µg/uge peginterferon alfa-2b. d: ribavirin dosis var 800 mg for patienter < 60 kg, 1.000 mg for patienter 60-75 kg, og 1.200 mg for patienter
c: subjects < 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients
c: forsøgspersoner < 75 kg fik 100 µg/uge peginterferon alfa-2b og forsøgspersoner ≥ 75 kg fik 150 µg/uge peginterferon alfa-2b. d: Ribavirin-dosis var 800 mg for patienter < 60 kg, 1.000 mg for patienter 60-75 kg, og 1.200 mg for patienter > 75 kg.
c: subjects < 75 kg received 100 μg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 μg/week peginterferon alfa-2b. d: Ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: forsøgspersoner < 75 kg fik 100 µg/uge pegyleret interferon alfa-2b og forsøgspersoner ≥ 75 kg fik 150 µg/uge pegyleret interferon alfa-2b. d: ribavirin dosering var 800 mg for patienter < 60 kg, 1.000 mg for patienter 60-75 kg og 1.200 mg for patienter > 75 kg.
c: subjects < 75 kg received 100 µg/week pegylated interferon alfa-2b and subjects ≥ 75 kg received 150 µg/week pegylated interferon alfa-2b. d: ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: forsøgspersoner < 75 kg fik 100 μg peginterferon alfa-2b/uge og forsøgspersoner ≥ 75 kg fik 150 μg peginterferon alfa-2b/uge. d: Ribavirindosis var 800 mg for patienter < 60 kg, 1.000 mg for patienter 60-75 kg og 1.200 mg for patienter > 75 kg.
c: subjects < 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: forsøgspersoner < 75 kg fik 100 μg/uge peginterferon alfa-2b og forsøgspersoner ≥ 75 kg fik 150 μg/uge peginterferon alfa-2b. d: Ribavirin-dosis var 800 mg for patienter < 60 kg, 1.000 mg for patienter 60-75 kg, og 1.200 mg for patienter > 75 kg.
c: subjects < 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
CA 94710 USA
Berkeley, CA 94710 United States
CA 94710 USA
Berkeley, CA 94710 USA
CA 94710 USA
United States
CA* uge 13-24
CA* wk 13-24
CA* uge 13-52
CA* wk 13-52
CA* uge 15-24
CA* wk 15-24
CA* uge 21-52
CA* wk 21-52
CA* uge 9-12
CA* wk 9-12
CA* uge 9-52
CA* wk 9-52
Ca-DTPA (calcium-trinatrium-diethylentriaminpentaacetat) eller
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or
Ca-DTPA (calciumtrinatrium-diethylentriaminpentaacetat) eller
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or
Ca-DTPA (trisodium kalcium dietylentriaminepentaacetat) eller
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or
Ca-EDTA (calcium-dinatrium-ethylendiamintetraacetat)
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-EDTA (calciumdinatrium-ethylendiamintetraacetat).
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-EDTA (kalcium disodium etylendiaminetetraacetat)
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
CA-raten mellem uge 9 og 12 var 35,9 % i vareniclin-armen sammenlignet med 15,6 % i placebo-armen (OR 3,35 (95 % CI 2,16-5,21)), og CA-raten mellem uge 9 og 52 hhv.
Continuous abstinence rate between weeks 9-12 was 35.9% in the varenicline treatment group versus 15.6% in the placebo group (OR 3.35 (95% CI 2.16-5.21)) and between weeks 9-52 was 20.3% versus 10.4% respectively (OR 2.36 (95% CI 1.40-3.98)).
Ca.
1.
Ca.
14.
Ca.
30
Ca.
9.
ca.
approx.
Ca. en -tredjedel af patienterne havde manglende respons på tidligere TNF-antagonistbehandling.
Approximately one-third of patients had failed prior TNF antagonist therapy.
Ca. halvdelen af de patienter, som udviklede absolut neutrofilocyttal < 1 x 109/l, fik det indenfor 8 uger efter behandlingens start.
Approximately half of the patients who developed an ANC < 1 x 109/ l did so within 8 weeks after starting therapy.
Ca. halvdelen af disse infektioner var grad 3 eller 4; hos 24,0 % af patienterne behandlet med Pom + LD-Dex og hos 22,8 % af patienterne, som fik HD-Dex.
Approximately half of those infections were Grade 3 or 4; 24.0% in Pom + LD-Dex-treated patients and 22.8% in patients who received HD-Dex.